Gain Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Gain Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $55.2K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $140.1K | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $165.0K | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $28.9K | Mar 25, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $55.2K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $132.6K | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $133.9K | Mar 23, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.16M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($20.41M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($22.27M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($17.59M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($13.89M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($3.58M) | Mar 25, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.71M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($20.35M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($22.25M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($17.78M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($13.83M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($3.48M) | Mar 25, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.21M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $10.79M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $11.52M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $8.38M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $7.16M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $2.26M | Mar 25, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.47M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($18.87M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($18.87M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($14.69M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($12.37M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($3.24M) | Mar 25, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $94.2K | Mar 25, 2022 |
| FY2021 | Dec 31, 2020 | $20.8K | Mar 25, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.82M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $12.12M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $18.61M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $24.10M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $38.99M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $9.60M | Mar 25, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.25M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.78M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $6.03M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $5.22M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $4.17M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $3.40M | Mar 25, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.56M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $7.34M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $12.58M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $18.88M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $34.82M | Mar 26, 2024 |
| FY2022 | Dec 31, 2020 | $6.20M | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | ($449.9K) | Mar 25, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($81.19M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($60.78M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($38.52M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($20.93M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($7.03M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($3.46M) | Mar 25, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.84M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $10.39M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $11.79M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $7.31M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $36.88M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $7.49M | Mar 25, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $401.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2024 | $438.5K | Mar 27, 2025 |
| FY2023 | Dec 31, 2023 | $567.9K | Mar 26, 2024 |
| FY2022 | Dec 31, 2022 | $603.4K | Mar 23, 2023 |
| FY2021 | Dec 31, 2021 | $694.3K | Mar 25, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 25, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 25, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 42.07M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 27.13M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 16.21M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 11.88M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | 11.88M | Mar 23, 2023 |
| FY2021 | Mar 16, 2021 | 4.02M | Mar 25, 2022 |
| FY2021 | Dec 31, 2020 | 3.54M | Mar 25, 2022 |